Misinformation about science is increasingly prevalent and a significant public health threat that the U.S. Food and Drug Administration will focus on fighting, incoming Commissioner Robert Califf said on February 17.
President Joe Biden said on December 27 he would support an effort to shorten COVID-19 quarantine requirements for those who test positive for the novel coronavirus if U.S. health authorities recommend such a change.
Union leaders representing 50,000 nurses and other U.S. medical staff reached a tentative agreement with Kaiser Permanente on November 13, averting a strike that could have disrupted patient care at hospitals.
Ten Republican state attorneys general sued on November 10 to stop the Biden administration’s requirement that millions of U.S. health workers get vaccinated against the coronavirus, saying it would worsen staff shortages.
The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.
Booster shots to bolster immunity against the coronavirus would be free and accessible, U.S. President Joe Biden said on Friday, one day after federal health agencies backed a booster rollout.
Advisers to the U.S. Food and Drug Administration voted on Sept. 17 to recommend Covid-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.
A U.S. judge in New York on Sept. 14 temporarily blocked the state from enforcing a requirement that healthcare workers receive Covid-19 vaccines against the wishes of employees with religious objections.
The COVAX vaccine facility delivered nearly 38.4 million doses of Covid-19 vaccines to 102 countries and economies across six continents six weeks after it began to roll out supplies, according to a statement on April 8.
AstraZeneca Plc will file for Japanese approval of the company’s Covid-19 vaccine as early as mid-February, the Yomiuri newspaper reported, marking the second vaccine maker to seek approval in Japan.